Harpoon Therapy Inc. (HARP)
(Delayed Data from NSDQ)
$10.59 USD
-0.41 (-3.73%)
Updated May 3, 2019 04:13 PM ET
After-Market: $10.33 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.59 USD
-0.41 (-3.73%)
Updated May 3, 2019 04:13 PM ET
After-Market: $10.33 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 0% and 3.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View
by Zacks Equity Research
Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance. Stock rises in pre-market.
Company News for Jan 9, 2024
by Zacks Equity Research
Companies In The News Are: HELE, CMC, NVDA, MRK, HARP.
Merck (MRK) to Strengthen Cancer Pipeline With Harpoon Buyout
by Zacks Equity Research
Merck's (MRK) Harpoon buyout is expected to strengthen its oncology pipeline by adding the latter's lead pipeline candidate, HPN328, a T cell engager being studied for SCLC and neuroendocrine tumors.
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical
by Zacks Equity Research
Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
Should You Buy Harpoon Therapeutics, Inc. (HARP) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ImmunoGen (IMGN) Gets FDA Priority Review for Elahere sBLA
by Zacks Equity Research
The FDA grants priority review to ImmunoGen's (IMGN) sBLA to convert the accelerated approval for Elahere to full approval for treating platinum-resistant ovarian cancer. A decision is due on Apr 5, 2024.
Harpoon Therapeutics, Inc. (HARP) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Harpoon Therapeutics, Inc. (HARP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stock to Buy for December 5th
by Zacks Equity Research
PDD, HARP and LEU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 5, 2023.
Is it a Good Idea to Invest in Harpoon (HARP) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in Harpoon Therapeutics (HARP) stock now may turn out to be a prudent move.
Wall Street Analysts Believe Harpoon Therapeutics, Inc. (HARP) Could Rally 40.5%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 40.5% upside potential for Harpoon Therapeutics, Inc. (HARP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Eli Lilly (LLY) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.
Merck (MRK) to Acquire Private Neuroscience Company for $610M
by Zacks Equity Research
Merck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund.
New Strong Buy Stocks for November 21st
by Zacks Equity Research
AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.
Fast-paced Momentum Stock Harpoon Therapeutics, Inc. (HARP) Is Still Trading at a Bargain
by Zacks Equity Research
Harpoon Therapeutics, Inc. (HARP) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Wall Street Analysts See a 92.31% Upside in Harpoon Therapeutics, Inc. (HARP): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Harpoon Therapeutics, Inc. (HARP) points to a 92.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
New Strong Buy Stocks for November 14th
by Zacks Equity Research
INTC, DIBS, HARP, EME and RWAY have been added to the Zacks Rank #1 (Strong Buy) List on November 14, 2023.
Harpoon Therapeutics, Inc. (HARP) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 106.98% and 120.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Foghorn Therapeutics Inc. (FHTX) delivered earnings and revenue surprises of 4.11% and 15.81%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of 26.19% and 2.58%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of -7.28% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Chinook Therapeutics (KDNY) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Chinook (KDNY) delivered earnings and revenue surprises of -6.25% and 292.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 500% and 59.45%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 10.87% and 246.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?